3/4
07:25 am
xfor
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference [Yahoo! Finance]
3/4
07:00 am
xfor
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
Medium
Report
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
3/2
04:30 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
07:22 am
xfor
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome [Yahoo! Finance]
2/27
07:13 am
xfor
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome [Yahoo! Finance]
Low
Report
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome [Yahoo! Finance]
2/27
07:00 am
xfor
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
Medium
Report
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
2/16
06:07 pm
xfor
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Medium
Report
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
2/3
07:52 am
xfor
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Low
Report
X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/3
07:00 am
xfor
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
Low
Report
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
2/2
04:01 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/19
01:53 am
xfor
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% [Yahoo! Finance]
Low
Report
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% [Yahoo! Finance]
1/6
10:47 am
xfor
Catalio-Backed Rhapsogen Names Renato Skerlj, Ph.D., Chief Executive Officer [Yahoo! Finance]
Low
Report
Catalio-Backed Rhapsogen Names Renato Skerlj, Ph.D., Chief Executive Officer [Yahoo! Finance]
12/30
04:16 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/24
07:01 pm
xfor
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? [Yahoo! Finance]
Medium
Report
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? [Yahoo! Finance]
12/23
04:14 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
04:43 pm
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/10
04:12 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
X4 Pharmaceuticals (NASDAQ:XFOR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/5
08:02 am
xfor
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $10.00 price target on by analysts at Stifel Nicolaus.
Low
Report
X4 Pharmaceuticals (NASDAQ:XFOR) was given a new $10.00 price target on by analysts at Stifel Nicolaus.